Latest News

Global melanoma incidence high and on the rise


 

FROM JAMA DERMATOLOGY

Public health efforts needed

In their editorial, Ms. Obeng-Kusi and Dr. Abraham pointed out that the study was hampered by the limited availability of cancer data from LMICs, leading the authors to estimate incidence and mortality rates based on proxy data, such as statistical modeling or averaged rates from neighboring countries.

They emphasized the need for going beyond the statistics: “Specific to cutaneous melanoma data, what is most important globally, knowing the exact numbers of cases and deaths or understanding the order of magnitude of the present and future epidemiology? No doubt the latter. Melanoma can be treated more easily if caught at earlier stages.”

Projections such as those provided by Dr. Arnold and colleagues could help to raise awareness of the importance of decreasing exposure to UV radiation, which accounts for three-fourths of all incident melanomas, the editorialists said.

The study was funded in part by a grant to coauthor Anna E. Cust, PhD, MPH. Dr. Cust reported receiving a fellowship from the Australian National Health and Medical Research Council outside the submitted work. Dr. Arnold had no conflicts of interested to disclose. Dr. Abraham reported financial relationships with various entities. Ms. Obeng-Kusi had no disclosures.

Pages

Recommended Reading

Medicare NCDs hinder access to cancer biomarker testing for minorities
MDedge Hematology and Oncology
“I didn’t want to meet you.” Dispelling myths about palliative care
MDedge Hematology and Oncology
Why dermatologists should support artificial intelligence efforts
MDedge Hematology and Oncology
High early recurrence rates with Merkel cell carcinoma
MDedge Hematology and Oncology
Complex link between gut microbiome and immunotherapy response in advanced melanoma
MDedge Hematology and Oncology
Ways to lessen toxic effects of chemo in older adults
MDedge Hematology and Oncology
Adverse skin effects of cancer immunotherapy reviewed
MDedge Hematology and Oncology
FDA approves new immunotherapy combo for metastatic melanoma
MDedge Hematology and Oncology
Few new cancer drugs replace current standards of care
MDedge Hematology and Oncology
Melanoma increasing, but is this overdiagnosis?
MDedge Hematology and Oncology